Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Solvay Pharmaceuticals |
---|---|
Information provided by: | Solvay Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00335153 |
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 6-12-months in subjects with advanced Parkinson's Disease (PD) and severe motor-fluctuations
Condition | Intervention | Phase |
---|---|---|
Advanced Parkinson's Disease |
Drug: Levodopa-Carbidopa intestinal gel Device: CADD-Legacy® 1400 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, 6-Months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor-Fluctuations |
Estimated Enrollment: | 250 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | November 2009 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Levodopa-Carbidopa intestinal gel
should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour);
Device: CADD-Legacy® 1400
ambulatory infusion pump
|
Ages Eligible for Study: | 30 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Staci Rokette | staci.rokette@solvay.com |
Study Director: | Global Clinical Director Solvay | Solvay Pharmaceuticals |
Responsible Party: | Solvay Pharmaceuticals ( Staci Rokette ) |
Study ID Numbers: | S187.3.004, 2006-005186-18 |
Study First Received: | June 8, 2006 |
Last Updated: | October 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00335153 |
Health Authority: | United States: Food and Drug Administration; Germany: Federal Institute for Drugs and Medical Devices; Australia: Department of Health and Ageing Therapeutic Goods Administration; New Zealand: Medsafe; Spain: Spanish Agency of Medicines; Portugal: National Pharmacy and Medicines Institute; Italy: The Italian Medicines Agency; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Finland: National Agency for Medicines; Czech Republic: State Institute for Drug Control; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); United Kingdom: Medicines and Healthcare Products Regulatory Agency; Russia: Ministry of Health and Social Development of the Russian Federation |
Efficacy Parkinson's Disease Severe Motor Fluctuations Dyskinesia |
Levodopa Carbidopa Levodopa-carbidopa Intestinal gel |
Levodopa Dopamine Ganglion Cysts Movement Disorders Parkinson Disease Carbidopa |
Basal Ganglia Diseases Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases Dyskinesias |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Antiparkinson Agents Dopamine Agents Enzyme Inhibitors Central Nervous System Agents Pharmacologic Actions |